Pharma outlines goals for oncology business as it moves to integrate ADC play Seagen 

Shift to product-focused company positioned German biotech for deal giving former Constellation assets to Swiss pharma

BioCentury’s analysis of 25 first-in-human studies presented at AACR 2023

Plus: Treeline takes rights to Hengrui’s EZH2 and updates from Cerevance, G1, Frequency, Ocular, Biocon and more 

Budget-priced $247M acquisition of epigenetics pioneer with slow-selling drug could deliver more value to Epizyme’s shareholders via CVR

German biotech offloads rights to pair of programs with potential in immunology, tightens focus on oncology

The strategy of in-licensing portfolios could be on its way out

Plus NDA ‘deficiencies’ sink Axsome shares, Hutchmed-Epizyme, Polivy and more